key: cord-0897990-aw6ys95c
authors: Krishnan, Shuba; Nordqvist, Hampus; Ambikan, Anoop T.; Gupta, Soham; Sperk, Maike; Svensson-Akusjärvi, Sara; Mikaeloff, Flora; Benfeitas, Rui; Saccon, Elisa; Ponnan, Sivasankaran Munusamy; Rodriguez, Jimmy Esneider; Nikouyan, Negin; Odeh, Amani; Ahlén, Gustaf; Asghar, Muhammad; Sällberg, Matti; Vesterbacka, Jan; Nowak, Piotr; Végvári, Ákos; Sönnerborg, Anders; Treutiger, Carl Johan; Neogi, Ujjwal
title: Metabolic perturbation associated with COVID-19 disease severity and SARS-CoV-2 replication
date: 2021-10-05
journal: Mol Cell Proteomics
DOI: 10.1016/j.mcpro.2021.100159
sha: f0f94966965cc0b7d437143a26b2a7e91927a5e4
doc_id: 897990
cord_uid: aw6ys95c

Viruses hijack host metabolic pathways for their replicative advantage. In this study, using patient-derived multi-omics data and in vitro infection assays, we aimed to understand the role of key metabolic pathways that can regulate severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) reproduction and their association with disease severity. We used multi-omics platforms (targeted and untargeted proteomics and untargeted metabolomics) on patient samples and cell line models along with immune phenotyping of metabolite transporters in patient blood to understand viral-induced metabolic modulations. We also modulated key metabolic pathways that were identified using multi-omics data to regulate the viral reproduction in vitro. COVID-19 disease severity was characterized by increased plasma glucose and mannose levels. Immune phenotyping identified altered expression patterns of carbohydrate transporter, GLUT1, in CD8(+) T-cells, intermediate and non-classical monocytes, and amino acid transporter, xCT, in classical, intermediate, and non-classical monocytes. In in vitro lung epithelial cell (Calu-3) infection model we found that glycolysis and glutaminolysis are essential for virus replication and blocking these metabolic pathways caused significant reduction in virus production. Taken together, we therefore hypothesized that SARS-CoV-2 utilizes and rewires pathways governing central carbon metabolism leading to the efflux of toxic metabolites and associated with disease severity. Thus, the host metabolic perturbation could be an attractive strategy to limit the viral replication and disease severity.

The global pandemic of coronavirus disease 2019 caused by the severe acute 54 respiratory syndrome coronavirus-2 (SARS-CoV-2) created a severe public health crisis 55 worldwide. Although most patients presented with mild to moderate or no symptoms, patients 56 having pre-existing metabolic disorders like diabetes, cardiovascular diseases, and obesity are at 57 risk for severe and critical cases of infection. Some recent observational studies indicate that 58 disease severity in COVID-19 patients is associated with plasma metabolic abnormalities that 59 include a shift towards amino acid and fatty acid synthesis, altered energy and lipid metabolism (1-60 3) and metabolic profile can identify the disease severity (4). However, metabolic regulation of an 61 individual always depends on several factors including age, gender, environmental factors, dietary 62 intake, and lifestyle. Such alterations in metabolic regulation can change rapidly or adapt to an 63 altered situation and sometimes have sustained effects over an extended period. The initial phase 64 of characterization of the metabolic landscape of COVID-19 and its association with disease 65 severity has urged the need to understand how metabolic reprogramming occurs during the acute 66 SARS-CoV-2 infection with the ultimate goal towards therapeutic intervention. 67

Viruses are known to exploit the host metabolic machinery to meet their biosynthetic demands for 68 optimal replication capacity (5). This cellular exploration is highly connected with the initial host-69 viral response, thereby determining the disease pathogenesis. Viral replication is dependent on 70 extracellular carbon sources such as glucose and glutamine. It induces a plethora of metabolic 71 alterations in host-cell including host central carbon metabolism, nucleotide, fatty acids and lipid 72 synthesis that modulate viral pathogenesis and host-response (6). Our recent in vitro multi-omics 73 studies have shown that the SARS-CoV-2 dysregulates PI3K/Akt/mTOR and HIF-1 signaling in 74 infected cells (7). These pathways regulate glycolysis by altering glucose transporters (GLUT) metabolite measurements were log2 scaled before differential analysis. Differential analysis was 146 done using R/Bioconductor package limma v3.42.2 (16). R package MUVR v0.0.973 (17) was 147 used for biomarker discovery. Random forest core modeling was selected from the package for 148 biomarker identification. Minimal-optimal variables selected by the model were considered as 149 biomarkers. Correlation analysis was performed using corr.test function from the package psych 150 v1.9.12.31 based on Spearman rank correlations. Untargeted protein raw data abundance was first 151 filtered for empty rows and quantile normalized. Functional analysis of the proteins was performed 152 using enrichr module of python package GSEAPY v 0.9.16 (https://pypi.org/project/gseapy/) (18), 153 where all the quantified proteins were considered as background. KEGG 2019 Human gene-set 154 library downloaded from Enrichr web resources was used for the enrichment test for molecular 155 pathway analysis. Functional analysis of the metabolites was carried out using Ingenuity Pathway 156 Analysis (IPA) software package. 157 Data visualization. Heatmaps were generated using R/Bioconductor package ComplexHeatmap 158 v2.2.0 (19) . Violin plots, box plots, bubble plots and volcano plots were made using R package 159 ggplot2 v3.3.2 respectively. A density plot was created using the R package ggridges v0.5.2. 160

Alluvial plot was made using ggalluvial v0.11.3 R package. Correlation pairs plot was made using 161 GGally v2.0.0 R package. The network was represented using Cytoscape ver 3.6.1 162 (https://cytoscape.org/). Protein-protein interactions were retrieved from STRING Db (v5.0) 163 (https://string-db.org/). Only interactions with high confidence (interaction score>0.7) from 164 databases and experiences were kept. 165

Flow Cytometry. Peripheral blood mononuclear cells (PBMCs) were subjected to flow cytometry 166 analysis. All samples were stained with live/dead fixable near IR dye (Invitrogen), and cell surface 167 markers were detected by incubating cells with relevant antibodies for 20min on ice in flow 168 cytometry buffer. All cells were fixed with 2% paraformaldehyde before acquiring a BD FACS 169 Symphony flow cytometer (BD Bioscience) and data were analyzed and compensated with FlowJo 170 10.6.2 (TreeStar Inc), Prism 8 (GraphPad Software Inc). The gating strategy is given in Fig S1. 

To identify the acute SARS-CoV-2 181 induced metabolic responses, we re-analyzed our previous untargeted quantitative proteomics data 182 on SARS-CoV-2 infected human cell lines including Calu-3 (lung), Caco-2 (colon), 293FT 183 (kidney) and Huh7 (liver) after 24h of infection restricted to metabolic pathways (9). 184

Calu-3 cells were seeded in 24-well plate, and after 185 72h of seeding, the cells were infected with SARS-CoV-2 at moi of 0.001 for 1h. Following 186 infection, the cells were treated with DMEM (Gibco, USA) which contained pyruvate (1mM) and 187 glutamine (4mM) as the basal carbon source and were supplemented with 5% FBS and different 188 concentrations of glucose (11.1mM, 22.2mM and 44.4mM) (Gibco, USA) and keeping basal 189 glucose concentration at 11.1mM, different concentrations of mannose (11.1mM, 22.2mM and 44.4mM) (Sigma-Aldrich, USA). Inhibitors of glycolysis, 2-deoxy-D-glucose (2-DG, Aldrich, USA), and glutaminolysis, diazo-5-oxo-L-norleucine (DON, Sigma-Aldrich, USA), were 192 reconstituted in water and cytotoxicity at different concentrations and 24h time point was 193 determined in Calu-3 cells using alamarBlue™ Cell Viability Reagent (Invitrogen, USA) according 194 to manufacturer's instructions. To determine the effect of these drugs on viral replication, following 195 1hpi (moi 0.001) the Calu-3 cells were treated with 2-DG (10mM) and DON (200M) respectively. 196 The supernatants were collected after 24hpi and the cells were lysed in TRI reagent (Zymo 197 Research, USA) and stored in -70°C for RNA extraction. 198

RT-qPCR Analysis. The virus production and infectivity were determined by qRT-PCR targeting 199

the viral E-gene in the supernatant and RNA extracted from the cells as described by us (7, 9) . 200

The purified RNA was reverse transcribed using a High-Capacity cDNA reverse transcription kit 201 (Table S3 ). The IgG CoV-2 antibody 215 test showed 10 of the HC were CoV-2 antibody positive (HC-CoV-2 Ab+, Fig S2) . Among the 216 COVID-19 patients, the classical co-morbidities were observed at 45% (13/29) in mild and at 66% 217 (8/12) in severe (p=0.3058). The samples were collected within median (IQR) 2 (2-3.5) days of 218 hospitalization [median (IQR) mild: 2 (1-3) and severe 3 (2-4); p=0.1170]. None of the patients 219 were on any known anti-COVID-19 treatment at the time of sample collection. 220

We performed targeted proteomics analyses (secretome) looking at 92 plasma proteins involved in 222 inflammatory responses. As expected, several cytokines and chemokines were significantly 223 elevated in COVID-19 patients (mild and severe) compared to HCs (HC and HC-CoV-2 Ab+), 224 including IL-6 (Fig 1a) . Pathway enrichment analyses of the proteins that were significantly 225 changed between HCs and COVID-19 patients revealed that the majority of altered proteins were 226 involved in cytokine-cytokine receptor interaction and chemokine signaling, followed by intestinal 227 network for IgA production, IL-17 signaling pathway, and Toll-like receptor signaling pathway; to 228 name the top five pathways (Fig 1b) . Interestingly, 11 proteins were altered between the mild and 229 severe COVID-19 patients (Fig 1a and 1c ): hepatocyte growth factor (HGF), pleiotrophin (PTN), 230 the chemokines CXCL12, CXCL13, and CCL23 (also known as macrophage inflammatory protein 231 3 or MIP-3), monocyte-chemotactic protein (MCP-3, also known as CCL7), interleukin 12 (IL-12), 232 tumor necrosis factor-like weak inducer of apoptosis (TWEAK), vascular endothelial growth factor 233 IL-12 which was increased in the mild group compared to both severe group and HCs (Fig 1a and  236 1b). Further, FASLG followed the opposite trend of being lower in COVID-19 patients compared 237 to HC and lowest in severe COVID-19 patients. This data showed that although IL-12 levels were 238 increased in COVID-19 patients compared to HC, the COVID-19 severe patients had reduced IL-239 12 compared to the mild patients. 240

The plasma metabolomic profile followed a pattern similar to the plasma proteomics. However, no 242 metabolites were significantly different between HC and HC-CoV-2 Ab+ (adj p>0.05). Therefore, 243

we combined the two groups as HC for further analysis. The distribution of all samples for 244 metabolite enrichment showed a fair separation between samples of HC and COVID-19 patients 245 (Fig 2a) . Differential analysis between COVID-19 patients and healthy individuals after adjusting 246 for age, gender, and BMI identified 444 significantly regulated metabolites (adj p<0.05), many of 247 which are lipids followed by amino acids (Fig 2b) . Metabolite set enrichment analysis of the 248 significant metabolites (adj p<0.05) identified amino acid-related pathways were most 249 predominantly affected during infection, as shown in Fig 2c. Hierarchical clustering of the 250 metabolites showed two clusters that had distinct enrichment patterns in COVID-19 infected 251 patients compared to HCs (Fig 2d) . Among these, amino acids such as glycine, proline, tryptophan, 252 alanine, histidine, glutamine, and arginine had lower levels in COVID-19 patients, while glutamate, 253 aspartate and phenylalanine had higher levels (Fig 2d and S3 ) as also observed in earlier studies 254

(1, 3, 21). Interestingly, metabolites of the central carbon metabolism including glycolysis 255 (glucose, 3-phosphoglycerate, pyruvate, lactate) and tricarboxylic acid (TCA) cycle (citrate, 256 aconitate, α-ketoglutarate) showed distinct changes when comparing HCs and COVID-19 patients

Next, we aimed to identify the metabolic signature in COVID-19 severe patients. Statistical 260 analysis found 88 metabolites that significantly differed in the severe group compared to mild 261 samples. Hierarchical clustering of the metabolites showed two clusters with moderately distinct 262 enrichment patterns in severe samples compared to mild samples (Fig 3a) . Metabolic pathway 263 enrichment analysis of the significant metabolites by IPA showed that several amino acid-related 264 pathways, IL-12 signaling and production in macrophages and insulin signaling pathways were 265 mainly dysregulated in the severe patient samples compared to mild ones (Fig 3b) . Next, we sought 266 to identify biomarkers that differentiate the severe and mild samples. Using R package MUVR that 267

is suitable for small sample size, a total of eight metabolites were identified as biomarkers ( Fig S5) . 268

After adjusting for age, gender, and BMI, seven remained significant of which four had higher 269 abundance and three had lower abundance in COVID-19 severe patients compared to the mild ones 270 (Fig 3c and S5 ). COVID-19 infection was associated with increased glutamate levels while glucose 271 and mannose were determinants of the severity of the disease (Fig 3d) and mannose can be 272 considered as a biomarker for disease severity. This data suggests alterations in the 273 glycolysis/gluconeogenesis, glutaminolysis and mannose metabolism in COVID-19 patients 274 irrespective of severity. Our targeted secretome data identified the C-type lectin receptor signaling 275 pathway as one of the top 28 ranked protein pathways that were significantly changed between 276

HCs and COVID-19 patients (Fig 1b) . MBLs are involved in complement activation through the 277 lectin pathways and has the ability to cause increased coagulopathy a feature often associated with 278 COVID-19 severity (22). We, therefore, measured plasma levels of soluble MBL using ELISA and 279 observed an increase in COVID-19 patients compared to HC. Strikingly, there was no significant showed increased MBL levels compared to HC (Fig 3e) . This data shows a prominent elevation of 282 MBL during COVID-19 infection that can persist over a prolonged duration of time after recovery. 283

MBLs play an important role in viral pathogenesis as they recognize the glycans present in the viral 284 envelope and subsequently activating antiviral immune response and T-cells (23, 24) . While the 285 role of circulating mannose level on activation of MBL mediated immune response is not known, 286

we assessed the correlation between them. We did not observe any correlation between MBL and 287 mannose in COVID-19 patients [Spearman correlation: 0.1437 (95%CI: -0.1806 -0.4399)]. We, 288 therefore, speculate that elevated MBL might not directly be the consequence of the higher plasma 289 mannose levels but regulated by SARS-CoV-2. 290

An earlier study reported an increased SARS-CoV-2 replication in monocytes in presence of 292 elevated glucose (25). However, a more recent study showed that despite SARS-CoV-2 efficiently 293 infects monocytes and monocyte-derived macrophages, their infection is abortive (26). Therefore, 294

to understand the role of sugars like glucose and mannose in SARS-CoV-2 infection, we performed 295 in vitro infection assays in Calu-3 cells with varying media concentrations of glucose (11.1, 22.2, 296 44.4mM) and mannose (0, 11.1, 22.2, 44.4mM) with 0.001moi. We did not observe any statistically 297 significant difference in virus production in the supernatant in the glucose/mannose concentrations 298 tested (p>0.05, Fig 3f) , while we found a significant reduction in viral E-gene expression at cellular 299 level with high glucose concentration of 44.4 mM (Fig 3g, p<0 .05). Supplementation with high 300 mannose did not cause any significant change in expression of the E-gene. Overall, our data 301 indicate that increased glucose levels but not mannose levels influence viral replication in vitro in 302

Calu-3 cells. Metabolite transporters are known to dictate immune cell activity by controlling access to nutrients, 307 thereby maintaining cellular homeostasis (27). Therefore, we next measured the expression of 308 carbohydrate transporters, GLUT1 (SLC2A1) and xCT (SLC7A11) that were one of the key 309 transporters of glucose/mannose and antiporter of glutamate respectively, in PBMCs of HC (n=19), 310 HC-CoV-2 Ab+ (n=9) and COVID-19 patients: mild (n=21) and severe (n=11) using flow 311 cytometry. Like other studies (28, 29), the relative frequency of lymphocytes significantly 312 decreased in COVID-19 patients than HCs, which was more prominent in severe patients (Fig 4a) . 313

In total lymphocytic populations the CD3 + T-cells were significantly reduced in COVID-19 severe 314 patients compared to mild patients and HCs (Fig 4b) . Although there was no difference in total 315 monocyte frequencies, we observed a mild increase in the frequency of intermediate monocytes 316

and a significant decrease in non-classical monocytes in the COVID-19 patients than HCs (Fig 4a  317 and 4b). This highlights the potential role of monocytes in COVID-19 as was also recently reported 318 in single-cell transcriptomics data (4, 30) and functional analysis on COVID-19 patient monocytes 319 (31). More than 98% CD8 + T-cells expressed GLUT1, and the surface expression of GLUT1 was 320 significantly higher in COVID-19 severe patients than mild and HCs (Fig 4c and 4d) . We also 321 found significantly higher surface expression of GLUT1 on the intermediate monocytes of 19 severe patients compared to HCs (Fig 4d) . While all classical and intermediate monocytes 323 expressed xCT, we observed a mild decrease in frequency of non-classical monocytes expressing 324 xCT in COVID-19 patients compared to HCs (Fig 4e) . The surface expression of xCT was higher 325 in classical and intermediate subpopulations of COVID-19 patients than HCs (Fig 4f) , emphasizing 326 the potential role of metabolite transporters in monocytes in COVID-19 infection and disease 327 severity.

Our previous study, together with other observational studies, indicate that SARS-CoV-2 infection 330 causes dysregulation of PI3K/Akt/mTOR and HIF-1 signaling pathway (7, 25, 32), and affect 331 mitochondrial functions (31, 33). Based on these findings, we hypothesized that the altered 332 extracellular glucose, mannose, and glutamate levels could be due to dysregulated carbohydrate 333 metabolism and mitochondrial function. Therefore, to identify the acute SARS-CoV-2 induced 334 metabolic responses we used our previous untargeted quantitative proteomics data on SARS-CoV-335 2 infected human cell lines including Calu-3 (lung), Caco-2 (colon), 293FT (kidney) and Huh7 336 (liver) that showed differential protein abundance in Calu-3 (6462 proteins), Caco-2 (177 proteins) 337

and Huh7 (4 proteins) after 24h of infection (9). The protein set enrichment analysis targeting the 338 metabolic pathways identified that most of the highly abundant proteins in infected Calu-3 cells 339 belonged to pentose phosphate pathway (PPP), fructose and mannose metabolism, as well as amino 340 acid biosynthesis (Fig 5a) . Proteins detected at a lower level in the infected cells mainly belonged 341 to TCA cycle, oxidative phosphorylation, and N-glycan biosynthesis (Fig 5a) . Parallelly, in 342 patients' metabolomic analysis we observed unbalanced levels of glycolysis, fructose and mannose 343 metabolism, and TCA cycle intermediates (Fig 2d and 3d) . We, therefore, focused our analysis on 344 the proteins (n=78) that are a part of glycolysis/gluconeogenesis, fructose and mannose metabolism 345 and TCA cycle (KEGG Human 2019) (Fig 5b) . A clear change in metabolic poise was observed 346 upon SARS-CoV-2 infection in Calu-3 cells where a majority of the significantly upregulated 347 proteins belonged to glycolysis/gluconeogenesis and fructose and mannose metabolism while most 348 of the proteins of the TCA cycle were significantly downregulated (Fig 5b and S6) . However, this 349 phenomenon was not observed in the other three cell culture models (Fig S7) . Only two out of 177 350 proteins identified were significantly different in Caco-2 cells (ACSS1 and PFKFB4) and no 351 differences were observed in Huh7 cells out of the four identified proteins in the three pathways mentioned above (Fig S6) . This shows that Calu-3 cells, which are lung epithelial cells, have a 353 distinct metabolic modulation caused by SARS-CoV-2 infection. Interestingly, although all the 354 mitochondrial TCA cycle enzymes were downregulated, cytosolic enzymes such as MDH1, IDH1, 355 ACO1 and ACLY that convert TCA cycle intermediates outside the mitochondria were upregulated 356 in infected Calu-3 cells (Fig 5c) . This points towards dysfunctional mitochondria caused by 357 COVID-19 infection. Alterations in mitochondrial DNA (mtDNA) copy number in circulating 358 blood cells can serve as a surrogate for mitochondrial dysfunction (34). Indeed, in our patient cohort 359 we observed a decreasing trend of the mtDNA copy numbers with the disease severity (Fig 5d) . In 360 addition to changes in glucose and glutamate (Fig 3d) , we also observed a significant increase in 361 metabolites such as pyruvate, lactate and α-ketoglutarate (more pronounced in mild patients) and 362 decrease in citrate and aconitate in COVID-19 patients compared to HCs (Fig S4) . This indicated 363 an impact of SARS-CoV-2 infection on glycolysis and glutaminolysis to meet biosynthetic and 364 bioenergetic demands. In order to determine the requirement of glycolysis and glutaminolysis for 365 optimal replication of SARS-CoV-2 in Calu-3 cells, we blocked these pathways using 2-DG 366 (10mM) and 6-diazo-5-oxo-L-norleucine (DON) respectively (200M). (Fig 5e) . The 367 concentrations were selected based on the cell cytotoxicity assays (Fig 5f) . Infectivity of SARS-368

CoV-2, quantified as relative E-gene levels in cells lysates, showed ~50-fold decrease in 2-DG 369 treated cells and >100-fold decrease in DON treated cells (Fig 5g) . This was also corroborated with 370 virus production in the cell culture supernatant, quantified by viral E-gene levels that decreased by 371 more than 2log10 RNA copies/ml in both 2-DG and DON treated cells compared to untreated cells 372 

In this study, we used metabolomics, proteomics and immunophenotyping to observe the effect of 379 SARS-CoV-2 infection on metabolic dysregulation in COVID-19 patients and re-analyzed our 380 earlier in vitro infection data in four different cell models to find out potential host metabolic 381 regulation during acute SARS-CoV-2 infection. Our study recognized the role of monocytes, 382 especially in severe COVID-19 disease. As expected, COVID-19 patients presented a cytokine 383 storm. Interestingly IL-12 plasma levels were decreased in severe compared to mild COVID-19 384 patients. Among the carbohydrates, plasma mannose emerged as a biomarker for disease severity, 385 but in vitro assays showed no effect of mannose on viral replication. Furthermore, host cellular 386 response following SARS-CoV-2 infection identified a strong acute metabolic adaptation in the 387 lung epithelial cells (Calu-3) by modulating central carbon metabolism and indicative of 388 mitochondrial dysfunction that is also observed in severe COVID-19 patients. Glycolysis and 389 glutaminolysis can be essential for virus replication and metabolic perturbations of these processes 390 can impede SARS-CoV-2 and could be an attractive antiviral strategy. 391

As reported, the cytokine storm syndrome is evident in COVID-19 patients (35). Several plasma 392 pro-inflammatory cytokines including IL-6 were elevated in both mild and severe COVID-19 393 patients. In our study, though we observed higher levels of soluble IL-12 in mild patients, the severe 394 patients showed IL-12 levels like HCs. Elevated plasma levels of IL-12 have also been described were an indicator of glycogenolysis as well as glucose tolerance and associated with the future risk of developing chronic diseases such as type 2 diabetes, cardiovascular diseases, and albuminuria 447 (46). In our study cohort, the incidence of type 2 diabetes was low in all study groups and can 448 therefore not explain the high plasma mannose levels in COVID-19 patients. This further strongly 449 suggests that increased mannose is an effect of SARS-CoV-2 infection. However, considering 450 recent research indicating a possibility of a bidirectional link between SARS-CoV-2 and diabetes, 451 it is tempting to speculate that increased mannose has a role to play in new-onset diabetes after 452 SARS-CoV-2 infection (47, 48) . favors SARS-CoV-2 infection and replication (25, 32) . While glutaminolysis has been implicated 493 as a carbon source for other human DNA and RNA viruses (6). Our data shows for the first time 494 that glutaminolysis is also crucial for SARS-CoV-2 infection and replication. The inhibition of 495 glutaminolysis has a larger effect on viral replication and production compared to the inhibition of 496 the glycolysis in lung cell model (Fig 5f and 5g ). Glutaminolysis is a process of converting 497 glutamine to TCA cycle intermediates and essential for biosynthesis of proteins, lipids, and nucleic 498 acids. Some viruses (e.g., herpes simplex virus 1, human cytomegalovirus, hepatitis C virus etc.) 499 use glutamine as an anaplerotic substrate to replenish TCA cycle via generation of α-ketoglutarate 500 (42, 54) . Recently, researchers have proposed that the metabolic reprogramming of glutamine in 501 SARS-CoV-2 can trigger pathogenesis. They further hypothesized that metabolic intervention of 502 glutaminolysis could be an antiviral strategy for 55) . Although the exact 503 underlying mechanism is unknown, our in vitro study shows that SARS-CoV-2 replication depends 504 on both glycolysis and glutaminolysis. 505

In conclusion, our patient based multi-omics studies and in vitro analysis emphasizes the need to 506 understand the host metabolic reprogramming due to acute SARS-CoV-2 infection. Among other 507 factors, the role of carbohydrate and amino acid transporters, mainly in the monocytic-macrophage 508 

COVID-19 infection alters kynurenine and fatty acid metabolism

Reveals False Positives, Batch Effects and Missing Values

UMAP: uniform manifold 605 approximation and projection

Elegant Graphics for Data Analysis -ggplot2

limma powers differential expression analyses for RNA-sequencing and microarray studies. 610

Variable 612 selection and validation in multivariate modelling

Enrichr: a comprehensive gene set enrichment 616 analysis web server 2016 update

Complex heatmaps reveal patterns and 618 correlations in multidimensional genomic data

A new mathematical model for relative quantification in real-time RT-620 PCR

Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to 626 SARS-CoV-2

Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in 23

Myeloid C-Type Lectin Receptors in Viral 25

Jimenez 636

Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-643 1alpha/Glycolysis-Dependent Axis

Dysregulation in COVID-19 Patients with Severe Respiratory Failure

A systematic review of 657 clinical and laboratory parameters associated with increased severity among COVID-19 patients

A single-cell atlas of the peripheral immune response in 662 patients with severe COVID-19

Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 667 pneumonia

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

SARS-CoV-2 and mitochondrial health: implications of lifestyle and ageing

IL-12 and viral infections

Metabolomic/lipidomic profiling of COVID-19 and 701 individual response to tocilizumab

Lactate dehydrogenase and susceptibility to 704 deterioration of mild COVID-19 patients: a multicenter nested case-control study

Viral activation of cellular metabolism

Metabolism in T Cells and Monocytes: New Perspectives in HIV Pathogenesis. EBioMedicine

Solute carrier transporters: the 712 metabolic gatekeepers of immune cells

Decreased GLUT1/NHE1 RNA 716 expression in whole blood predicts disease severity in patients with COVID-19

COVID-19 infection 726 may cause ketosis and ketoacidosis

O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2

Mannose efflux from the cells: a potential source of 51

Glycomic analysis 735 of host response reveals high mannose as a key mediator of influenza severity

Host cell glutamine 749 metabolism as a potential antiviral target

The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory 752 response

Fig 1. Targeted plasma proteomics in COVID-19 patients. (a) Heatmap of Z-score 757 transformed quantitative measurements of all proteins detected by the immuno-oncology panel

Names of proteins which are identified as significant in any of the 761 statistical analysis printed. (b) KEGG pathway enrichment analysis results of significantly 762 changed proteins between healthy control (HC + HC-CoV-2 Ab+) and COVID-19 (hospitalized 763 mild+hospitalized severe) groups. (c) Violin plot of significantly regulated (Mann-Whitney U 764 test) proteins between hospitalized mild and hospitalized severe, *adj p<0.05, **adj p<0.01. 765 for quantitative metabolite measurements plotted in 2-dimensional space after performing 767 dimensionality reduction using UMAP. (b) Stacked bar plots visualizing percentage of 768 metabolites significantly changed between healthy control (HC + HC-CoV-2 Ab+) and COVID-769 19 (hospitalized mild + hospitalized severe) group concerning their corresponding super-770 pathways and sub-pathways. (c) Metabolic set enrichment analysis using the significantly 771 enriched metabolites between HCs and COVID-19 patients. The size of the bubble indicates 772 adjusted p-values. (d) Heatmap of log2 scaled and Z-score transformed measurements of 773 metabolites significantly changed between healthy control (HC + HC-CoV-2 Ab+) and COVID-774 19 (hospitalized mild + hospitalized severe) groups. Column annotation represents each patient 775 sample and the corresponding groups

Column 781 annotation represents each patient sample and the corresponding groups. Rows are metabolites 782 hierarchically clustered based on Euclidean distance and complete linkage method. (b) Alluvial 783 plot representing pathways resulted from IPA pathway enrichment analysis using all metabolites 784 that differs significantly between hospitalized mild and severe groups. (c) Volcano plot showing 785 all the metabolites that differ significantly between hospitalized mild and hospitalized severe 786 groups. (d) Box plots of key metabolites glutamate, glucose, and mannose. Adjusted p values 787 determined by LIMMA is shown

Glucose, mannose, and glutamate transporters in COVID-19 severity: (a) Percentage 795 of total lymphocytes and monocytes in all 4 patient groups; (b) Percentage of PBMC 796

subpopulations, CD3 + T-cells of lymphocytes, CD4 + T-cells (of CD3 + cells) CD8 + T-cells

Median values are indicated by lines. (c) Density plot of percentage of CD8 + T-cells, 800 IM and NCM expressing GLUT1. Histograms show percentage of cells expressing GLUT1 801 (x-axis) and GLUT1 read density of each sample (y-axis). The median percentage of cells 802 expressing GLUT1 is shown for each patient group

Histograms show percentage of cells expressing xCT (x-axis) and xCT read density of each 805

The median percentage of cells expressing xCT is shown for each patient group. 806 (f) MFI of xCT in CM, IM and NCM in all four patient groups. In all the panels the median 807 values are indicated by lines, p-values are determined by Mann-Whitney U test

01, and ***p<0

Cell-specific regulation of central carbon metabolic pathways by SARS-CoV-2: (a)